Tranexamic acid to prevent operation in chronic subdural haematoma (TORCH): study protocol for a randomised placebo-controlled clinical trial

S Immenga, R Lodewijkx, Y B W E M Roos, S Middeldorp, C B L M Majoie, H C Willems, W P Vandertop, D Verbaan, S Immenga, R Lodewijkx, Y B W E M Roos, S Middeldorp, C B L M Majoie, H C Willems, W P Vandertop, D Verbaan

Abstract

Background: Chronic subdural haematoma (cSDH) occurs mainly in the elderly. Surgical evacuation is effective, but in these old, often frail, patients with multi-comorbidity, surgery carries significant risks for future cognitive functioning and loss of independency. Therefore, a growing interest is noted for a non-surgical treatment with medication such as tranexamic acid (TXA). In five small retrospective series, this antifibrinolytic drug showed a beneficial effect on the spontaneous resolution of the haematoma, and with that, the necessity for surgery.

Methods: For this randomised, placebo-controlled clinical multicentre trial, all cSDH patients, over 50 years old with mild symptoms (Glasgow Coma Score (GCS) ≥ 14, modified National Institutes of Health Stroke Scale (mNIHSS) ≤ 4), a midline shift of ≤ 10 mm and in whom a primary conservative treatment is chosen, are eligible for study participation. After informed consent, 140 patients will be randomised to receive either TXA 500 mg or placebo two times daily for 28 days. The primary outcome is the necessity for surgery within 12 weeks; secondary outcomes are cSDH volume, neurological impairment (mNIHSS), falling incidents, cognitive functioning (Montreal Cognitive Assessment (MOCA)), performance in activities of daily living (Barthel and Lawton score), functional outcome (modified Rankin Scale (mRS)), quality of life (Short Form Health Survey (SF-36) and EuroQol 5-Dimension Health Survey (EQ-5D)), mortality and the use of care and health-related costs (Medical Consumption Questionnaire (iMCQ) and Productivity Cost Questionnaire (iPCQ)) at 12 weeks and 6 months.

Discussion: This phase III trial investigating the efficacy of TXA to prevent surgery for cSDH is the first in including patients using anticoagulants and mentally incompetent patients, since these comprise a significant part of the target population. Also, this study is one of the first to prospectively measure functional outcome and quality of life in cSDH patients. Final results of this study are expected in 2024.

Trial registration: Dutch Trial Registry (Nederlands Trial Register) NL6584 . Registered on 11 November 2017 ClinicalTrials.gov NCT03582293 . Registered on 11 July 2018 EU Clinical Trials Register 2017-004311-40 . Registered on 29 March 2018.

Keywords: Activities of daily living; Antifibrinolytic agents; Conservative treatment; Haematoma, Subdural, Chronic; Neurosurgery; Quality of life; Tranexamic acid.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Participant timeline

References

    1. Sambasivan M. An overview of chronic subdural hematoma: experience with 2300 cases. Surg Neurol. 1997;47(5):418–422. doi: 10.1016/S0090-3019(97)00188-2.
    1. Tagle P, et al. Chronic subdural hematoma: a disease of elderly people. Rev Med Chil. 2003;131(2):177–182. doi: 10.4067/S0034-98872003000200007.
    1. Adhiyaman V, et al. Chronic subdural haematoma in the elderly. Postgrad Med J. 2002;78(916):71–75. doi: 10.1136/pmj.78.916.71.
    1. Greenberg MS. Handbook of neurosurgery 7th ed. In: Chapter 27 Head trauma. Thieme Medical Pub 2010. p. 896–902. ISBN 1604063262.
    1. Balser D, Farooq S, Mehmood T, Reyes M, Samadani U. Actual and projected incidence rates for chronic subdural hematomas in United States Veterans Administration and civilian populations. J Neurosurg. 2015;123(5):1209–1215. doi: 10.3171/2014.9.JNS141550.
    1. Baechli H, Nordmann A, Bucher HC, Gratzl O. Demographics and prevalent risk factors of chronic subdural haematoma: results of a large single-center cohort study. Neurosurg Rev. 2004;27(4):263–266. doi: 10.1007/s10143-004-0337-6.
    1. Berghauser Pont LM, et al. Ambivalence among neurologists and neurosurgeons on the treatment of chronic subdural hematoma: a national survey. Acta Neurol Belg. 2013;113(1):55–59. doi: 10.1007/s13760-012-0130-1.
    1. Yang S, Zhang X, Jin Y. Spontaneous resolution of nontraumatic chronic subdural hematoma associated with anti-aggregation therapy. J Craniofac Surg. 2014;25(4):363–365. doi: 10.1097/SCS.0000000000000814.
    1. Brennan PM, Kolias AG, Joannides AJ, Shapey J, Marcus HJ, Gregson BA, Grover PJ, Hutchinson PJ, Coulter IC. The management and outcome for patients with chronic subdural hematoma: a prospective, multicenter, observational cohort study in the United Kingdom. J Neurosurg. 2017;127(4):732–739. doi: 10.3171/2016.8.JNS16134.
    1. Poulsen FR, Munthe S, Søe M, Halle B. Perindopril and residual chronic subdural hematoma volumes six weeks after burr hole surgery: a randomized trial. Clin Neurol Neurosurg. 2014;123:4–8. doi: 10.1016/j.clineuro.2014.05.003.
    1. Berghauser Pont LM, et al. The role of corticosteroids in the management of chronic subdural hematoma: a systematic review. Eur J Neurol. 2012;19(11):1397–1403. doi: 10.1111/j.1468-1331.2012.03768.x.
    1. Stary JM, Hutchins L, Vega RA. Tranexamic acid for recurring subdural hematomas following surgical evacuation: a clinical case series. J Neurol Surg A. 2016;77:422–426. doi: 10.1055/s-0036-1584212.
    1. Kageyama H, Toyooka T, Tsuzuki N, Oka K. Nonsurgical treatment of chronic subdural hematoma with tranexamic acid. J Neurosurg. 2013;119(2):332–337. doi: 10.3171/2013.3.JNS122162.
    1. Tanweer O, Frisoli FA, Bravate C, Harrison G, Pacione D, Kondziolka D, Huang PP. Tranexamic acid for treatment of residual subdural hematoma after bedside twist-drill evacuation. World Neurosurg. 2016;91:29–33. doi: 10.1016/j.wneu.2016.03.062.
    1. Kutty RK, Peethambaran AK, Sunilkumar, Anilkumar M. Conservative treatment of chronic subdural hematoma in HIV-associated thrombocytopenia with tranexamic acid. J Int Assoc Provid AIDS Care. 2017;16(3):211–214. doi: 10.1177/2325957416680294.
    1. Wakabayashi Y, et al. Effect of Gorei-san with tranexamic acid for preventing recurrence of chronic subdural hematoma. No Shinkei Geka. 2012;40(11):967–971.
    1. Ioro-Morin C, et al. Tranexamic acid in chronic subdural hematomas (TRACS): study protocol for a randomized controlled trial. Trials. 2016;17(1):235. doi: 10.1186/s13063-016-1358-5.
    1. Cusimano MD et al. Tranexamic acid in the treatment of residual chronic subdural hematoma (TRACE). In: . . Accessed 10 Nov 2020
    1. CRASH-2 trial collaborators Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23–32. doi: 10.1016/S0140-6736(10)60835-5.
    1. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, Bussières JS, McGuinness S, Byrne K, Chan MTV, Landoni G, Wallace S. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med. 2017;376(2):136–148. doi: 10.1056/NEJMoa1606424.
    1. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001;86(2):714–715. doi: 10.1055/s-0037-1616122.
    1. Gaillard S, Dupuis-Girod S, Boutitie F, Rivière S, Morinière S, Hatron PY, Manfredi G, Kaminsky P, Capitaine AL, Roy P, Gueyffier F, Plauchu H, The ATERO Study Group Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12(9):1494–1502. doi: 10.1111/jth.12654.
    1. Chornenki NLJ, et al. Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: a systematic review and meta-analysis. Thromb Res. 2019;179:81–86. doi: 10.1016/j.thromres.2019.05.003.
    1. Brainlab Cranial Planning . Accessed 10 Nov 2020
    1. Meyer BC, Hemmen TM, Jackson CM, Lyden PD. Modified National Institutes of Health Stroke Scale for use in stroke clinical trials: prospective reliability and validity. Stroke. 2002;33(5):1261–1266. doi: 10.1161/01.STR.0000015625.87603.A7.
    1. Nasreddine ZS, The Montreal Cognitive Assessment et al. MoCA: a brief screening tool form mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. doi: 10.1111/j.1532-5415.2005.53221.x.
    1. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md Stade Med J. 1965;14:61–65.
    1. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–186. doi: 10.1093/geront/9.3_Part_1.179.
    1. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54(12):1044–1054. doi: 10.1136/jnnp.54.12.1044.
    1. Saris-Baglama RN, Dewey CJ, Chisholm GB, et al. QualityMetric health outcomes scoring software 4.0. Lincoln, RI: QualityMetric Incorporated; 2010. p. 138.
    1. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–343. doi: 10.3109/07853890109002087.
    1. Institute for Medical Technology Assessment . Accessed 16 Jan 2018
    1. Cohen J. Statistical power analysis for the behavioral sciences. 2. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc.; 1988.
    1. Immenga S, Vandertop WP, Verbaan D. Voorkomt tranexaminezuur een operatie bij chronisch subduraal hematoom? De TORCH studie. Ned Tijdschr Geneeskd. 2018;162:D3202.
    1. Website TORCH study. . Accessed 10 Nov 2020
    1. TORCH Datamanagement plan via DCC’s DMPOnline . Accessed 10 Nov 2020
    1. Castor Electronic Data Capture. . Accessed 10 Nov 2020
    1. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg . Accessed 29 Feb 2016
    1. (). Accessed 10 Nov 2020
    1. Versteegh M, et al. Dutch tariff for the five-level version of EQ-5D. Value Health. 2016;19(4):343–352. doi: 10.1016/j.jval.2016.01.003.
    1. Lukes AS, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(4):865–875. doi: 10.1097/AOG.0b013e3181f20177.
    1. Gaillard S, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12(9):1494–1502. doi: 10.1111/jth.12654.
    1. Geisthoff UW, Seyfert UT, Kübler M, Bieg B, Plinkert PK, König J. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid – a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res. 2014;134(3):565–571. doi: 10.1016/j.thromres.2014.06.012.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren